These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 22251978
21. A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. Sipahi I, Celik S, Tozun N. JAMA Intern Med; 2014 Jan; 174(1):150-1. PubMed ID: 24247291 [No Abstract] [Full Text] [Related]
22. Update on dabigatran for stroke prevention in atrial fibrillation. Henry DM. Conn Med; 2011 Sep; 75(8):479-83. PubMed ID: 21980679 [No Abstract] [Full Text] [Related]
23. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Shah SV, Gage BF. Circulation; 2011 Jun 07; 123(22):2562-70. PubMed ID: 21606397 [Abstract] [Full Text] [Related]
24. Extensive postoperative ecchymosis in a patient taking dabigatran. Wagner CA, Oberoi N, Ahluwalia PK. J Minim Invasive Gynecol; 2013 Jun 07; 20(1):127-30. PubMed ID: 23312256 [Abstract] [Full Text] [Related]
25. The trouble with dabigatran. Charlton B, Redberg R. BMJ; 2014 Jul 23; 349():g4681. PubMed ID: 25055830 [No Abstract] [Full Text] [Related]
26. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee. Can J Cardiol; 2011 Jul 23; 27(1):74-90. PubMed ID: 21329865 [Abstract] [Full Text] [Related]
27. Dabigatran for stroke prevention in all patients with atrial fibrillation? Hunchuck JE, Lake JD. Pharmacotherapy; 2011 Aug 23; 31(8):725-8. PubMed ID: 21923597 [No Abstract] [Full Text] [Related]
28. [New anticoagulants: "efficacy and safety" or "efficacy or safety"]. Pernod G. J Mal Vasc; 2011 Dec 23; 36(6):337-8. PubMed ID: 21907510 [No Abstract] [Full Text] [Related]
30. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force. Circulation; 2011 Mar 15; 123(10):1144-50. PubMed ID: 21321155 [No Abstract] [Full Text] [Related]
31. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Circulation; 2012 Feb 07; 125(5):669-76. PubMed ID: 22215856 [Abstract] [Full Text] [Related]
35. Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment. Pontillo D, Patruno N. J Cardiovasc Med (Hagerstown); 2015 Feb 07; 16(2):142. PubMed ID: 25539158 [No Abstract] [Full Text] [Related]